Alerta

INCORPORATION OF ADDITIONAL SENSORS INTO ADAPTATION OF AID SYSTEMS

Resumen de: AU2023343209A1

Disclosed are techniques, devices and systems that provide adjustments to parameter settings of an insulin delivery algorithm based on inputs from a number of generic sensor devices. A majority of the generic sensor devices provide sensor readings that are unused as inputs to a drug deliver algorithm. The generic sensor devices may be operable to detect characteristics, such as changes in a state of a user. A processor may evaluate a sensor reading provided by a particular sensor with respect to a sensor baseline reading for the particular sensor. Using the result of the evaluation, the processor may calculate an adjustment to a parameter setting or settings of a medication delivery algorithm. A dosage of medication may be modified based on the adjustment of the parameter setting or settings.

ZERO GAP AUTOMATED INSULIN DELIVERY TREATMENT SYSTEM

Resumen de: US2025099674A1

Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.

PERSONALIZED CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Resumen de: WO2025060173A1

A personalized closed-loop artificial pancreas system, comprising: a measurement module (100) for continuously measuring the blood glucose level of a patient; an infusion module (102) for infusing insulin into the body of the patient; and a program module (101) for controlling the measurement module (100) and the infusion module (102). At least on the basis of the blood glucose level measured by the measurement module (100), the program module (101) generates an insulin infusion instruction, and controls the infusion module (102) to perform infusion; the program module (101) comprises a user interface; in response to the input of the patient, the program module (101) executes functions of corresponding meal patterns; the meal patterns comprise a high-carbohydrate pattern and a normal-carbohydrate pattern; and on the basis of the input of the patient, the program module (101) executes the function of the high-carbohydrate pattern or the normal-carbohydrate pattern. The present invention can be adapted to people having different carbohydrate consumption habits, improve the adaptability of a closed-loop artificial pancreas to different people, and enable people having different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.

CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Resumen de: WO2025060174A1

Disclosed in the present invention is a closed-loop artificial pancreas system, comprising: a measuring module, used for continuously measuring the blood glucose level of a patient; an infusion module, used for infusing insulin into the body of a patient; and a program module, used for controlling the measuring module and the infusion module, wherein at least on the basis of the blood glucose level measured by the measuring module, the program module generates an insulin infusion instruction, and controls the infusion module to perform infusion. The system uses an infusion strategy of pre-infusion and supplemental infusion, the amount of insulin for the pre-infusion is related to an estimated meal size during the pre-infusion, and the amount of insulin for the supplemental infusion is related to an estimated meal size during the supplemental infusion. There is no need to explicitly determine a meal size. On the basis of an estimated meal size, the system determines the amount of insulin to be infused. On one hand, the pressure of needing to accurately determine a meal size is reduced, and on the other hand, considering the dynamic effects of a meal and a high-dose infusion on the blood glucose level, the infusion strategy of pre-infusion and supplemental infusion is used, so that the blood glucose level of a patient is maintained at an ideal level.

DECISION SUPPORT FOR GLUCOSE-KETONE SENSOR

Resumen de: WO2025064882A2

A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in the bodily fluid of a patient. The application is configured to display at least one of (1) a current ketone level and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time that the ketone levels are above at least one predetermined threshold level. The application is also configured to determine if the current ketone level is above the at least one predetermined threshold level, and in response to determining that the current ketone level is above the at least one predetermined threshold level, output an alarm, wherein the alarm is outputted periodically while the current ketone level is above the at least one predetermined threshold level.

METHODS, DEVICES, AND SYSTEMS FOR ADJUSTING LABORATORY HBA1C VALUES

Resumen de: WO2025064603A1

A method for determining a time for obtaining laboratory glycated hemoglobin measurements can include receiving at least one glucose level for a subject during at least one time period, receiving a first measured glycated hemoglobin (HbAlc) level for the subject corresponding to a beginning of a first time period of the at least one time period, determining a first calculated glycated hemoglobin (HbAlc) level corresponding to the first time period, determining for the first time period a second calculated glycated hemoglobin (HbAlc) level using a first offset value, determining for the first time period a third calculated glycated hemoglobin (HbAlc) level using a second offset value, calculating a first difference between the first calculated glycated hemoglobin (HbAlc) level and the second calculated glycated hemoglobin (HbAlc) level, calculating a second difference between the first calculated glycated hemoglobin (HbAlc) level and the third calculated glycated hemoglobin (HbAlc) level, and generating an alert notification to obtain a second measured glycated hemoglobin (HbAlc) level for the subject in response to a determination that the first difference or the second difference is above a first predetermined threshold value.

CONTROL SYSTEM FOR BLOOD GLUCOSE MONITORING AND MANAGEMENT

Resumen de: WO2025059863A1

A control system for blood glucose monitoring and management. A first working mode of the control system is to control a blood glucose monitoring device to perform real-time blood glucose monitoring. The control system enters a second working mode on the basis of a trigger condition, and the second working mode at least comprises controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling an insulin infusion device to perform insulin infusion. By means of the trigger condition, the control system enters the second working mode of at least controlling the blood glucose monitoring device to perform real-time blood glucose monitoring and controlling the insulin infusion device to perform insulin infusion from the first working mode of controlling the blood glucose monitoring device to perform real-time blood glucose monitoring, so that a patient is prevented from accidentally entering unnecessary or unauthorized working modes, and the safety of blood glucose monitoring and management of the patient is improved.

WIRELESS COMMUNICATION MANAGEMENT IN INFUSION PUMP SYSTEMS

Resumen de: WO2025064967A1

Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system and a smartphone or other multi-purpose consumer electronic device. Communications among these devices can be coordinated to increase efficiency and conserve battery power.

EARLY RECOGNITION OF CHANGE TO PATHOPHYSIOLOGIC STATE OF DYSGLYCEMIA

Resumen de: WO2025064557A1

Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.

METHOD TO AVOID HYPOGLYCEMIA BY MINIMIZING LATE POST-PRANDIAL INSULIN INFUSION IN AID SYSTEM

Resumen de: WO2025064417A1

Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

FORMULATIONS

Resumen de: US2025099593A1

According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.

CONTINUOUS BLOOD GLUCOSE MONITORING SYSTEM

Resumen de: US2025098989A1

Provided is a continuous blood glucose monitoring system, including a container shell, and a spring, a continuous blood glucose detection apparatus and a trigger structure which are arranged inside the container shell. One end of the spring is connected to an interior of the container shell, and the other end of the spring is connected to the continuous blood glucose detection apparatus. The trigger structure is arranged on a side edge of the interior of the container shell, a protruding portion is arranged on the trigger structure, which is unlockably locked with the continuous blood glucose detection apparatus. The continuous blood glucose detection apparatus includes: an apparatus shell and a circuit board arranged in the apparatus shell; a probe assembly being connected to the circuit board; and a pressure detection sensor connected to the circuit board, which being configured to detect a pressure change signal on the apparatus shell.

BODY ATTACHABLE UNIT FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025098991A1

Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.

WIRELESS COMMUNICATION MANAGEMENT IN INFUSION PUMP SYSTEMS

Resumen de: US2025099678A1

Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system and a smartphone or other multi-purpose consumer electronic device. Communications among these devices can be coordinated to increase efficiency and conserve battery power.

SITE TRACKING BASED ON CONNECTIVITY IN INFUSION PUMP SYSTEMS

Resumen de: US2025099679A1

Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.

INSULIN DELIVERY METHODS, SYSTEMS AND DEVICES

Resumen de: US2025099680A1

An insulin delivery monitoring system that includes an insulin delivery device and a controller configured to perform or control performance of operations. A method of insulin delivery includes determining a correction dose of insulin and triggering an alert.

TECHNIQUES TO DETERMINE PATTERNS IN BLOOD GLUCOSE MEASUREMENT DATA AND A USER INTERFACE FOR PRESENTATION THEREOF

Resumen de: AU2023271749A1

Disclosed are techniques, devices and computer products in which a processor is operable to access blood glucose measurement values and insulin data from a data memory. Based on the blood glucose measurement values the processor may be operable to identify high events that exceed an upper target blood glucose set point and low events in which blood glucose measurement values are below a lower target blood glucose set point. Rules may be applied to the high events and low events. Based on a result of the rules, high event patterns may be identified as well as a low event pattern. A respective pattern weight may be applied to each identified high event and each identified low and a graphical user interface may be populated with a number of high event patterns and for a number of low event patterns.

BODY ATTACHABLE UNIT FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: EP4527292A1

Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.

IMPROVED ACCURACY CONTINUOUS GLUCOSE MONITORING METHOD, SYSTEM, AND DEVICE

Resumen de: EP4527291A2

A method and a system for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a short-time glucose prediction horizon to estimate the value of a CGM signal at a time t+PH with a noise estimation algorithm.

CONTINUOUS GLUCOSE SENSOR AND MOUNTING ASSEMBLY

Resumen de: US2023301557A1

Embodiments of the present disclosure relate to systems, devices and methods for continuous glucose monitoring. In some embodiments, a continuous glucose monitoring (CGM) device is provided that includes a subcutaneous implantable electrochemical sensing probe (sensor). The sensor is planar and comprises counter and working electrodes that are deposited at both sides of the sensing probe. A biocompatible layer deposited at the entire sensor circumference minimizes inflammatory reaction. A reel to reel production process provides “per sensor” layers' deposition at predefined spots on a base sheet during displacement between production stations. Production processes are conducted initially at one side of the base sheet followed by production processes on the opposite side. Sensor by sensor working electrode surface areas and layers' thickness are measured and “per sensor” data (“dry” parameters) is stored according to base sheet identifiers that could be implemented by printed or etched markings or else by other means such as RFID. In addition, batch parameters are measured on a sample basis (in vitro “wet” parameters). A factory calibration algorithm analyzes “per lot” sample of sensors' performance (in vitro “wet” parameters in glucose solutions) as well as individual sensor measurement and combines the data in a calibration algorithm to calculate individual sensor calibration parameters and data is programmed back to the individual sensor.

MEASUREMENT OF SUSCEPTIBILITY TO DIABETIC FOOT ULCERS

Resumen de: EP4464242A2

The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.

ASSESSING DISEASE RISKS FROM USER CAPTURED IMAGES

Resumen de: US2025095862A1

In some examples, an apparatus, such as a mobile phone can include an input module such as a touch screen, a camera, a processor, and computer readable medium. The camera captures one or more images of a person. The processor can use a single machine learning model to estimate the human body features of the person based on the captured images, and use the human body features to generate a disease risk assessment value associated with diabetes and cardiovascular disease risks. The human body features can include at least one or more of: 3D body shape, or body shape indicators; and one or more of: blood flow, blood pressure, heart rate, respiratory rate, heart rate variability, cardiac workload, irregular heartbeats, or stress index. The machine learning model can be trained over a set of training images.

METHOD TO AVOID HYPOGLYCEMIA BY MINIMIZING LATE POST-PRANDIAL INSULIN INFUSION IN AID SYSTEM

Resumen de: US2025090754A1

Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

CONTINUOUS GLUCOSE MONITOR COMMUNICATION WITH MULTIPLE DISPLAY DEVICES

Resumen de: US2025094109A1

A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.

A BOTULINUM TOXIN SYRINGE

Nº publicación: US2025090758A1 20/03/2025

Solicitante:

WEBB THOMAS [AU]
WEBB Thomas

Resumen de: US2025090758A1

A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.